Sharemaestro Newsreel

Lloyd Minor (BIIB) files Form 144 for 593-share NASDAQ stock sale

Lloyd Minor, an insider at Biogen Inc. (BIIB), has filed a Form 144 indicating a planned or recent sale of 593 shares of company common stock. These shares were acquired on June 9, 2026, through restricted stock vesting as compensation. The filing also reports …

AbbVie (ABBV) Lifted Guidance, Has The Market Already Priced It In?

Merck & Co., Inc. (NYSE:MRK) Updates FY 2026 Earnings Guidance

Sanofi’s MenQuadfi approval expanded to infants from six weeks in Europe

Sanofi's MenQuadfi vaccine has

AbbVie Seeks at Least $8 Billion in Debt to Fund Apogee Deal

AbbVie Inc. is reportedly looking to raise at least $8 billion, and potentially up to $10 billion, through an investment-grade bond offering. The pharmaceutical giant intends to use these funds to finance a portion of its acquisition of Apogee Therapeutics Inc. The final size …

Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine at Johnson & Johnson, is set to retire after a distinguished 21-year career, during which she significantly grew the company's Innovative Medicine business to over $60 billion in annual revenue. Tom Cavanaugh, currently Company Group …

Is Pfizer (PFE) A Bargain Following Its Earnings Beat And 2026 Guidance Lift?

An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’

Analysts are describing a potential merger between AstraZeneca and Bristol Myers Squibb as "odd," despite its potential to create a major cancer-drug powerhouse. The Financial Times reported early-stage talks, leading to AstraZeneca shares closing lower and Bristol Myers Squibb remaining flat. This merger would …

Bristol Myers Squibb, AstraZeneca reportedly weigh $400B merger

U.K. drugmaker AstraZeneca and New Jersey-based Bristol Myers Squibb are reportedly in early-stage talks for a potential $400 billion merger. If successful, this tie-up would create the world’s fourth-largest drugmaker by market value and the largest by revenue, uniting their strengths in oncology, immunology, …

Guggenheim Adjusts Price Target on AbbVie to $288 From $261, Maintains Buy Rating

Guggenheim has increased its price target for AbbVie (NYSE: ABBV) to $288 from $261, while reiterating a Buy rating on the stock. This adjustment comes amidst other analyst revisions for AbbVie, with Rothschild & Co Redburn also adjusting its target to $285 and Oppenheimer …

Amgen Inc. Cloud Data Breach Exposes Patient PHI in 2026 Cybersecurity Incident Analysis

In July 2026, Amgen Inc. disclosed a cybersecurity incident involving unauthorized access to its third-party-hosted cloud storage systems, resulting in the exfiltration of proprietary data and patient PHI. The company promptly initiated its incident response, engaged forensics experts, and notified the SEC. While the …

Pfizer Post Loss on Higher Revenue

Pfizer reported a second-quarter loss of $248 million, or 4 cents a share, despite a 3% increase in revenue to $15.03 billion. The company's revenue growth was driven by its oncology business, which helped to offset declining sales of its Covid-19 products. This contrasts …

Jefferies Adjusts Price Target on Merck & Co. to $152 From $147, Keeps Buy Rating

Jefferies has increased its price target for Merck & Co. to $152 from $147, while maintaining a Buy rating on the stock. This adjustment comes amidst recent news regarding Merck's Q2 non-GAAP loss, sales rise, and updated 2026 outlook, as well as several other …

Merck lifts sales forecast as newer drugs gain momentum (MRK:NYSE)

Merck reported strong second-quarter results, surpassing Wall Street expectations due to the continued success of its cancer drug Keytruda and the strong uptake of newer drugs like Winrevair. The drugmaker posted an adjusted loss of $0.13 per share, which was better than estimated. This …

Earnings Flash (MRK) Merck & Co., Inc. Reports Q2 Revenue $16.61B, vs. FactSet Est of $16.37B

Merck & Co., Inc. (MRK) reported its Q2 revenue of $16.61 billion, exceeding FactSet's estimate of $16.37 billion. This financial update was released alongside several other announcements, including a revised full-year profit forecast and adjusted EPS and sales expectations for 2026. The company's stock …

Merck posts better-than-expected second-quarter results on Keytruda strength

Merck reported higher-than-expected second-quarter sales of $16.61 billion, driven primarily by its top-selling cancer drug Keytruda, which saw a 5% sales increase to $8.37 billion. Despite a quarterly loss due to a $5.7 billion acquisition charge, the company raised its full-year revenue forecast to …

Caterpillar, Pfizer and 3 Stocks to Watch Heading Into Tuesday

As U.S. stock futures trade higher, several companies are poised for investor attention on Tuesday. Caterpillar (NYSE: CAT) and McDonald's (NYSE: MCD) are expected to report quarterly earnings, while Palantir Technologies (NASDAQ: PLTR), Snap Inc (NYSE: SNAP), and Pfizer Inc (NYSE: PFE) have already …

Pfizer raises revenue outlook after quarterly earnings top estimates

Pfizer beat Wall Street expectations for its second-quarter 2026 earnings and raised its full-year revenue guidance midpoint. The company reported adjusted earnings of $0.77 per share and revenue of $15.03 billion, driven by growth in new and acquired products, which offset declines in its …

Hilltop National Bank Has $1.04 Million Position in Amgen Inc. $AMGN

Hilltop National Bank significantly reduced its stake in Amgen Inc. by 58.3% in the second quarter, now holding 2,860 shares valued at approximately $1.04 million. Despite this, institutional investors collectively own 76.5% of Amgen, which recently declared a quarterly dividend of $2.52 per share. …

Amgen Inc. $AMGN Holdings Cut by CX Institutional

CX Institutional significantly reduced its stake in Amgen Inc. by 32% in Q2, selling 12,252 shares and retaining 25,985 shares valued at $9.41 million. Despite a reported data breach posing a near-term risk, analysts maintain a consensus "Hold" rating with a $357 price target, …

Novartis AG (NVS) Investor Outlook: Analyzing Market Position Amidst a Strong Dividend Yield and Analyst Ratings

Novartis AG (NVS) is a global pharmaceutical leader with a market cap of $296.8 billion, known for its stable market position and innovative pipeline. The company offers an attractive 3.04% dividend yield with a 71.60% payout ratio, making it appealing to income-focused investors. While …

Amgen Inc. (NASDAQ:AMGN) Given Average Recommendation of "Hold" by Brokerages

Amgen Inc. (NASDAQ:AMGN) has received a consensus "Hold" recommendation from thirty research firms, with an average 12-month price target of $357.00. While new medicines and potential expansion into type 2 diabetes offer growth opportunities, the company faces a significant near-term risk from a reported …

Novo Nordisk shares slide after guidance disappoints investors

Gilead's $8.45 Q2 per-share loss reflects $11.2B in acquisition research costs

Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026

Amgen (AMGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Amgen (AMGN) Q2 Earnings and Revenues Surpass Estimates

Amgen (NASDAQ:AMGN) Delivers Strong Q2 CY2026 Numbers, Guides for Strong Full-Year Sales

Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?

Pfizer Covid Pill Revenue Plunges 95%. The Stock Is Rising Anyway.

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Pfizer (PFE) Q2 Earnings and Revenues Top Estimates

Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

Merck & Co., Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:MRK) 2026-08-04

Bristol Myers Squibb Company (BMY) Hit a 52 Week High, Can the Run Continue?

AstraZeneca Stock Drops 7% as Merger Talks With Bristol Myers Squibb Surface